FamiCord AG (V3V.DE) XETRA
3.91
-0.05(-1.26%)
Currency In EUR
- General
- Statistics
- Historical Data
- Profile
- Financials
FamiCord AG
Sector
Healthcare
Industry
Medical - Care Facilities
Employees
783
First IPO Date
March 27, 2007
Key Executives
| Name | Title | Pay | Year Born |
| Jakub Julian Baran | Chairman of the Management Board & Chief Executive Officer | 436,973 | N/A |
| Thomas Pfaadt | Chief Financial Officer & Member of Management Board | 168,409 | N/A |
| Tomasz Franciszek Baran | Vice President of the Management Board & CMO | 307,755 | N/A |
| Santiago Luengo | Managing Director of Secuvita | 0 | N/A |
| Conelia Wittke-Kothe | CCO & Member of Management Board | 0 | N/A |
Description
VITA 34 AG engages in the collection, processing, and storage of stem cells from umbilical cord blood and tissue in Germany, Spain, and internationally. It also develops cell therapeutic procedures; cell and gene therapies; cryopreservation of endogenous immune cells; and CAR-T. In addition, the company manufactures advanced therapy medicinal products based on mesenchymal stem cells for experimental treatment by specialized medical institutions; preserves stem cells from perinatal tissue and adult body fat; and engages in the contract manufacturing of pharmaceutical intermediates. VITA 34 AG was founded in 1997 and is based in Leipzig, Germany.
